2013 American Transplant Congress

May 18-22, 2013 in Seattle, Washington

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Addition of Anti-CMV Ig to Routine CMV Prophylaxis in EBV High Risk Kidney Transplant Recipients Is Associated with Reduced PTLD Incidence

A. Shields, E. Woodle, R. Alloway, S. Safdar, S. Huang, M. Cardi
Adherence with Immunosuppressive Therapy: Results to 4 Years after Kidney Transplantation in the Mycophenolic Acid Observational Renal Transplant (MORE) Study

D. Tsapepas, A. Langone, L. Chan, A. Wiland, K. McCague, M. Chisholm-Burns
Adjunctive Bortezomib Therapy for Treatment of Antibody Mediated Rejection in Kidney Transplant Recipients

J. McDermott, J. Lee, M. Aull, T. Muthukumar, C. Hartono, D. Serur, J. Lee, V. Sharma, J. Kim, A. Watkins, S. Kapur, M. Suthanthiran, D. Dadhania
Advagraf Immunosuppression Initiation in Kidney and Liver Transplant Recipients: 3 Month-Interim Analysis of a French Multicenter Observational Study

D. Cantarovich, O. Cointault, A. Loupy, B. Roche, L. Rostaing, N. Kamar, E. Cassuto, M. Kessler, S. Dharancy, G. Pageaux
Adverse Events of Over-Immunosuppression Are Dependent on Tofacitinib Exposure in Kidney Transplant (KT) Patients

S. Busque, F. Vincenti, H. Tedesco Silva, P. O'Connell, M. Tortorici, N. Lawendy, W. Wang, G. Chan
Age and Antimetabolites: Appropriate Candidate Selection Drives Success

T. Horwedel, D. Brennan, L. Bowman
Age Disparities in Discussions about Kidney Transplantation among Dialysis Patients

M. Salter, M. McAdams DeMarco, A. Law, B. Jaar, R. Parekh, D. Segev
Aggravation of Post-Ischemic Liver Injury by Overexpression of IGFBP-3

J. Yang, H. Yu, B. Park, H. Hwang, B. Cho
Aggregate Annual Health Care Expenditures Associated with Lung Transplantation in the United States: 1988-2011

R. Evans
Aggregate Impacts of the CMS CoP on Patient and Donor Characteristics

K. Schnier, V. Sadiraj, J. Cox, N. Turgeon

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z